Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymalfasin as an Enhancer of COVID-19 Vaccine Response in Older Adults
NCT06821100Phase 1Recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of thymosin alpha 1 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Houston Methodist Research Institute. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 52 weeks. Started Dec 2024; status: recruiting.
02
Drugs
thymosin alpha 1
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06821100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06821100.